10-Q: Applied DNA Sciences Reports Q3 2024 Results, Faces Going Concern Doubts

Applied DNA Sciences reported its Q3 2024 financial results, highlighting a net loss and raising concerns about its ability to continue as a going concern.

Summary

• Applied DNA Sciences reported a net loss of $3.77 million for the nine months ended June 30, 2024, and a loss of $1.85 million for the three months ended June 30, 2024.
• The company's operating cash flow was negative $10.46 million for the nine-month period.
• Revenue decreased significantly, primarily due to a sharp decline in COVID-19 testing revenues, with total revenue for the nine months ended June 30, 2024 at $2.62 million compared to $12.59 million for the same period in 2023.
• The company's gross profit also decreased significantly to $771,980 for the nine months ended June 30, 2024, compared to $5.45 million for the same period in 2023.
• The company had cash and cash equivalents of $10.44 million as of June 30, 2024.
• The company has raised approximately $10.5 million through a public offering in May 2024.
• The company is developing its Therapeutic DNA Production Services, including Linea DNA and Linea IVT platforms, and is expanding its MDx Testing Services with a focus on pharmacogenomics testing.
• The company received full approval from the New York State Department of Health for its pharmacogenomics testing services in June 2024.
• The company is facing challenges related to its minimum bid price on the Nasdaq and has received a delisting notice.
• The company plans to implement a reverse stock split to regain compliance with Nasdaq listing rules.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with significant losses, declining revenues, and a going concern warning. While there are some positive developments in product development and regulatory approvals, the overall sentiment is negative due to the company's financial instability and delisting risk.

Positives

• The company successfully raised $10.5 million through a public offering in May 2024.
• The company received full approval from the New York State Department of Health for its pharmacogenomics testing services.
• The company is actively developing its Therapeutic DNA Production Services, including Linea DNA and Linea IVT platforms.
• The company is expanding its MDx Testing Services with a focus on genetic testing.
• The company has completed manufacturing process development work on its Linea RNAP to increase production scale and reduce unit costs.

Negatives

• The company reported a significant net loss of $3.77 million for the nine months ended June 30, 2024.
• The company's operating cash flow was negative $10.46 million for the nine-month period.
• The company experienced a substantial decrease in revenue, primarily due to a decline in COVID-19 testing.
• The company's gross profit decreased significantly compared to the previous year.
• The company received a delisting notice from Nasdaq due to non-compliance with minimum bid price requirements.
• The company has substantial doubt about its ability to continue as a going concern.

Risks

• The company faces substantial doubt about its ability to continue as a going concern due to recurring net losses and negative operating cash flow.
• The company's reliance on additional financing may lead to dilution of ownership for existing stockholders.
• The company's non-compliance with Nasdaq's minimum bid price requirements could lead to delisting, negatively impacting its business and stock price.
• The company's laboratory developed tests (LDTs) may become subject to additional regulatory requirements, increasing costs and causing delays.
• The company's ability to achieve the benefits expected from the acquisition of Spindle Biotech, Inc. is not guaranteed.
• The company's future revenue growth is dependent on the success of its Therapeutic DNA Production Services and MDx Testing Services, which are still under development.
• The company's May 2024 Series Warrants are not exercisable until stockholder approval is obtained, and if not obtained, the warrants will have no value.

Future Outlook

The company expects future growth in revenues to be derived from its Therapeutic DNA Production Services and its MDx Testing Services, as the latter transitions to a focus on genetic testing. The company plans to expand its contract development and manufacturing operation (CDMO) for the manufacture of synthetic DNA for use in the production of nucleic acid-based therapies. The company also plans to leverage its Therapeutic DNA Production Services to develop and monetize Linea DNA-based therapeutic or prophylactic vaccines for high-value veterinary health indications.

Management Comments

• Management believes the Linea DNA platform holds several important advantages over existing cell-based plasmid DNA manufacturing platforms.
• Management believes the integrated Linea IVT platform offers advantages over conventional mRNA production to therapy developers and manufacturers.
• Management plans to leverage its PGx Testing Services to provide testing services to large entities, self-insured employers and healthcare providers.
• Management intends to effect a reverse stock split of its shares of Common Stock to enable it to regain compliance with the Minimum Bid Price Requirement.

Industry Context

The company operates in the biotechnology sector, focusing on DNA and RNA technologies. The company's Therapeutic DNA Production Services are positioned to capitalize on the growing market for nucleic acid-based therapeutics, including mRNA therapies. The company's MDx Testing Services are aligned with the trend towards personalized medicine and pharmacogenomics. The company's DNA Tagging and Security Products and Services address the increasing need for supply chain security and product authentication.

Comparison to Industry Standards

• The company's revenue decline is significant compared to the growth seen in the broader biotechnology sector, particularly in areas like mRNA therapeutics.
• The company's negative operating cash flow and net losses are concerning, especially when compared to more established companies in the industry.
• The company's reliance on equity financing is common for early-stage biotech companies, but the current financial situation raises concerns about its long-term sustainability.
• The company's development of Linea DNA and Linea IVT platforms is in line with the industry's focus on advanced manufacturing technologies for nucleic acid-based therapies.
• The company's expansion into pharmacogenomics testing is a strategic move to capitalize on the growing demand for personalized medicine.
• The company's challenges with Nasdaq listing compliance are not uncommon for smaller biotech companies, but the potential delisting poses a significant risk.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's financial instability and potential delisting.
• Employees may experience uncertainty due to the company's going concern doubts and potential restructuring.
• Customers may be concerned about the company's ability to fulfill contracts and provide ongoing services.
• Suppliers and creditors may face increased risk due to the company's financial challenges.

Next Steps

• The company plans to implement a reverse stock split to regain compliance with Nasdaq listing rules.
• The company is obligated to call a subsequent stockholder meeting to seek to obtain Warrant Stockholder Approval for the May 2024 Series Warrants.
• The company plans to complete its GMP Site 1 to produce DNA critical starting materials for mRNA manufacturing.
• The company plans to offer additional capacity for Linea DNA IVT templates and Linea DNA materials manufactured under GMP suitable for use as a biologic, drug substance and/or drug product.
• The company will continue to seek to raise additional working capital through public equity, private equity or debt financings.

Key Dates

Keywords

Therapeutic DNA Production Services, MDx Testing Services, Linea DNA, Linea IVT, Pharmacogenomics, COVID-19 testing, Reverse stock split, Nasdaq delisting, Going concern, Warrants, RNA polymerase, GMP, DNA Tagging, Supply chain security